-
1
-
-
17344374265
-
Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: Safety, immunogenicity, and efficacy during the first 12 months of follow-up
-
Armijos, R. X., M. M. Weigel, H. Aviles, R. Maldonado, and J. Racines. 1998. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J. Infect. Dis. 177:1352-1357.
-
(1998)
J. Infect. Dis.
, vol.177
, pp. 1352-1357
-
-
Armijos, R.X.1
Weigel, M.M.2
Aviles, H.3
Maldonado, R.4
Racines, J.5
-
2
-
-
33749648396
-
Immunotherapy for drug-refractory mucosal leishmaniasis
-
Badaro, R., et al. 2006. Immunotherapy for drug-refractory mucosal leishmaniasis. J. Infect. Dis. 194:1151-1159.
-
(2006)
J. Infect. Dis.
, vol.194
, pp. 1151-1159
-
-
Badaro, R.1
-
3
-
-
18944378937
-
Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: Evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis
-
Basu, R., et al. 2005. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol. 174:7160-7171.
-
(2005)
J. Immunol.
, vol.174
, pp. 7160-7171
-
-
Basu, R.1
-
4
-
-
3042521098
-
Improved prediction of signal peptides: SignalP 3.0
-
Bendtsen, J. D., H. Nielsen, G. von Heijne, and S. Brunak. 2004. Improved prediction of signal peptides: SignalP 3.0. J. Mol. Biol. 340:783-795.
-
(2004)
J. Mol. Biol.
, vol.340
, pp. 783-795
-
-
Bendtsen, J.D.1
Nielsen, H.2
Von Heijne, G.3
Brunak, S.4
-
5
-
-
70350569335
-
Optimized subunit vaccine protects against experimental leishmaniasis
-
Bertholet, S., et al. 2009. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27:7036-7045.
-
(2009)
Vaccine
, vol.27
, pp. 7036-7045
-
-
Bertholet, S.1
-
6
-
-
59849102406
-
KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major
-
Bhaumik, S., R. Basu, S. Sen, K. Naskar, and S. Roy. 2009. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine 27:1306-1316.
-
(2009)
Vaccine
, vol.27
, pp. 1306-1316
-
-
Bhaumik, S.1
Basu, R.2
Sen, S.3
Naskar, K.4
Roy, S.5
-
7
-
-
0035001263
-
Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease
-
Campos-Neto, A., et al. 2001. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect. Immun. 69:4103-4108.
-
(2001)
Infect. Immun.
, vol.69
, pp. 4103-4108
-
-
Campos-Neto, A.1
-
8
-
-
0022369062
-
Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis
-
Carvalho, E. M., R. Badaro, S. G. Reed, T. C. Jones, and W. D. Johnson, Jr. 1985. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J. Clin. Invest. 76:2066-2069.
-
(1985)
J. Clin. Invest.
, vol.76
, pp. 2066-2069
-
-
Carvalho, E.M.1
Badaro, R.2
Reed, S.G.3
Jones, T.C.4
Johnson Jr., W.D.5
-
9
-
-
34547870667
-
Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD(4+) T cells
-
Coler, R. N., Y. Goto, L. Bogatzki, V. Raman, and S. G. Reed. 2007. Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD(4+) T cells. Infect. Immun. 75:4648-4654.
-
(2007)
Infect. Immun.
, vol.75
, pp. 4648-4654
-
-
Coler, R.N.1
Goto, Y.2
Bogatzki, L.3
Raman, V.4
Reed, S.G.5
-
10
-
-
17444429293
-
Second-generation vaccines against leishmaniasis
-
Coler, R. N., and S. G. Reed. 2005. Second-generation vaccines against leishmaniasis. Trends Parasitol. 21:244-249.
-
(2005)
Trends Parasitol.
, vol.21
, pp. 244-249
-
-
Coler, R.N.1
Reed, S.G.2
-
11
-
-
0036073291
-
Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis
-
DOI 10.1128/IAI.70.8.4215-4225.2002
-
Coler, R. N., et al. 2002. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stressinducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun. 70:4215-4225. (Pubitemid 34790930)
-
(2002)
Infection and Immunity
, vol.70
, Issue.8
, pp. 4215-4225
-
-
Coler, R.N.1
Skeiky, Y.A.W.2
Bernards, K.3
Greeson, K.4
Carter, D.5
Cornellison, C.D.6
Modabber, F.7
Campos-Neto, A.8
Reed, S.G.9
-
12
-
-
34250303350
-
H1 cells define a correlate of vaccine-mediated protection against Leishmania major
-
DOI 10.1038/nm1592, PII NM1592
-
Darrah, P. A., et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13:843-850. (Pubitemid 47038186)
-
(2007)
Nature Medicine
, vol.13
, Issue.7
, pp. 843-850
-
-
Darrah, P.A.1
Patel, D.T.2
De Luca, P.M.3
Lindsay, R.W.B.4
Davey, D.F.5
Flynn, B.J.6
Hoff, S.T.7
Andersen, P.8
Reed, S.G.9
Morris, S.L.10
Roederer, M.11
Seder, R.A.12
-
13
-
-
53449090936
-
Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein
-
Fernandes, A. P., et al. 2008. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 26:5888-5895.
-
(2008)
Vaccine
, vol.26
, pp. 5888-5895
-
-
Fernandes, A.P.1
-
14
-
-
0035850989
-
Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections
-
DOI 10.1016/S0264-410X(01)00322-X, PII S0264410X0100322X
-
Ghosh, A., W. W. Zhang, and G. Matlashewski. 2001. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20:59-66. (Pubitemid 32905314)
-
(2001)
Vaccine
, vol.20
, Issue.1-2
, pp. 59-66
-
-
Ghosh, A.1
Zhang, W.W.2
Matlashewski, G.3
-
15
-
-
64449087496
-
Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection
-
Goto, Y., et al. 2009. Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection. Vaccine 27:2884-2890.
-
(2009)
Vaccine
, vol.27
, pp. 2884-2890
-
-
Goto, Y.1
-
16
-
-
34748876077
-
Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant
-
Goto, Y., L. Y. Bogatzki, S. Bertholet, R. N. Coler, and S. G. Reed. 2007. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formulated in adjuvant. Vaccine 25:7450-7458.
-
(2007)
Vaccine
, vol.25
, pp. 7450-7458
-
-
Goto, Y.1
Bogatzki, L.Y.2
Bertholet, S.3
Coler, R.N.4
Reed, S.G.5
-
17
-
-
60849092883
-
Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs
-
Goto, Y., et al. 2009. Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs. Vet. Parasitol. 160:215-220.
-
(2009)
Vet. Parasitol.
, vol.160
, pp. 215-220
-
-
Goto, Y.1
-
18
-
-
26644448719
-
Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals
-
Gradoni, L., et al. 2005. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 23:5245-5251.
-
(2005)
Vaccine
, vol.23
, pp. 5245-5251
-
-
Gradoni, L.1
-
19
-
-
0021075679
-
Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis
-
Haldar, J. P., S. Ghose, K. C. Saha, and A. C. Ghose. 1983. Cell-mediated immune response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect. Immun. 42:702-707.
-
(1983)
Infect. Immun.
, vol.42
, pp. 702-707
-
-
Haldar, J.P.1
Ghose, S.2
Saha, K.C.3
Ghose, A.C.4
-
20
-
-
0034193027
-
In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease
-
Himmelrich, H., et al. 2000. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J. Immunol. 164:4819-4825.
-
(2000)
J. Immunol.
, vol.164
, pp. 4819-4825
-
-
Himmelrich, H.1
-
21
-
-
0034605714
-
Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: A randomised, double-blind, BCG-controlled trial in Sudan
-
Khalil, E. A., et al. 2000. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356:1565-1569.
-
(2000)
Lancet
, vol.356
, pp. 1565-1569
-
-
Khalil, E.A.1
-
22
-
-
77952725081
-
Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine
-
Kumar, R., et al. 2010. Evaluation of ex vivo human immune response against candidate antigens for a visceral leishmaniasis vaccine. Am. J. Trop. Med. Hyg. 82:808-813.
-
(2010)
Am. J. Trop. Med. Hyg.
, vol.82
, pp. 808-813
-
-
Kumar, R.1
-
23
-
-
0030588671
-
The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice: A tissue-dependent pattern controlled by the Lsh and MHC loci
-
Leclercq, V., M. Lebastard, Y. Belkaid, J. Louis, and G. Milon. 1996. The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice: a tissue-dependent pattern controlled by the Lsh and MHC loci. J. Immunol. 157:4537-4545.
-
(1996)
J. Immunol.
, vol.157
, pp. 4537-4545
-
-
Leclercq, V.1
Lebastard, M.2
Belkaid, Y.3
Louis, J.4
Milon, G.5
-
24
-
-
0025609915
-
Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide
-
Liew, F. Y., Y. Li, and S. Millott. 1990. Tumor necrosis factor-alpha synergizes with IFN-gamma in mediating killing of Leishmania major through the induction of nitric oxide. J. Immunol. 145:4306-4310.
-
(1990)
J. Immunol.
, vol.145
, pp. 4306-4310
-
-
Liew, F.Y.1
Li, Y.2
Millott, S.3
-
25
-
-
77958184848
-
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis
-
Llanos-Cuentas, A., et al. 2010. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 28:7427-7435.
-
(2010)
Vaccine
, vol.28
, pp. 7427-7435
-
-
Llanos-Cuentas, A.1
-
26
-
-
40049107841
-
Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis
-
Miret, J., et al. 2008. Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine 26:1585-1594.
-
(2008)
Vaccine
, vol.26
, pp. 1585-1594
-
-
Miret, J.1
-
27
-
-
34250853431
-
Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis
-
Moreno, J., et al. 2007. Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis. Vaccine 25:5290-5300.
-
(2007)
Vaccine
, vol.25
, pp. 5290-5300
-
-
Moreno, J.1
-
28
-
-
0029030456
-
Expression cloning of a protective Leishmania antigen
-
Mougneau, E., et al. 1995. Expression cloning of a protective Leishmania antigen. Science 268:563-566.
-
(1995)
Science
, vol.268
, pp. 563-566
-
-
Mougneau, E.1
-
29
-
-
0033785362
-
Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment
-
Murray, H. W., A. Jungbluth, E. Ritter, C. Montelibano, and M. W. Marino. 2000. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect. Immun. 68:6289-6293.
-
(2000)
Infect. Immun.
, vol.68
, pp. 6289-6293
-
-
Murray, H.W.1
Jungbluth, A.2
Ritter, E.3
Montelibano, C.4
Marino, M.W.5
-
30
-
-
0027164877
-
Role and effect of IL-2 in experimental visceral leishmaniasis
-
Murray, H. W., G. D. Miralles, M. Y. Stoeckle, and D. F. McDermott. 1993. Role and effect of IL-2 in experimental visceral leishmaniasis. J. Immunol. 151:929-938.
-
(1993)
J. Immunol.
, vol.151
, pp. 929-938
-
-
Murray, H.W.1
Miralles, G.D.2
Stoeckle, M.Y.3
McDermott, D.F.4
-
31
-
-
77956432699
-
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis
-
Nascimento, E., et al. 2010. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 28:6581-6587.
-
(2010)
Vaccine
, vol.28
, pp. 6581-6587
-
-
Nascimento, E.1
-
32
-
-
56949106494
-
First generation leishmaniasis vaccines: A review of field efficacy trials
-
Noazin, S., et al. 2008. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine 26:6759-6767.
-
(2008)
Vaccine
, vol.26
, pp. 6759-6767
-
-
Noazin, S.1
-
33
-
-
40649091062
-
Vaccines for leishmaniasis in the fore coming 25 years
-
Palatnik-de-Sousa, C. B. 2008. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 26:1709-1724.
-
(2008)
Vaccine
, vol.26
, pp. 1709-1724
-
-
Palatnik-De-Sousa, C.B.1
-
34
-
-
21044441505
-
Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum
-
DOI 10.1016/j.vaccine.2005.02.009, PII S0264410X05002690
-
Rafati, S., et al. 2005. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 23:3716-3725. (Pubitemid 40692418)
-
(2005)
Vaccine
, vol.23
, Issue.28
, pp. 3716-3725
-
-
Rafati, S.1
Nakhaee, A.2
Taheri, T.3
Taslimi, Y.4
Darabi, H.5
Eravani, D.6
Sanos, S.7
Kaye, P.8
Taghikhani, M.9
Jamshidi, S.10
Rad, M.A.11
-
35
-
-
0035858106
-
A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major
-
DOI 10.1016/S0264-410X(01)00081-0, PII S0264410X01000810
-
Rafati, S., A. H. Salmanian, T. Taheri, M. Vafa, and N. Fasel. 2001. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine 19:3369-3375. (Pubitemid 32710285)
-
(2001)
Vaccine
, vol.19
, Issue.25-26
, pp. 3369-3375
-
-
Rafati, S.1
Salmanian, A.-H.2
Taheri, T.3
Vafa, M.4
Fasel, N.5
-
36
-
-
32844459122
-
Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis
-
Rafati, S., F. Zahedifard, and F. Nazgouee. 2006. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 24:2169-2175.
-
(2006)
Vaccine
, vol.24
, pp. 2169-2175
-
-
Rafati, S.1
Zahedifard, F.2
Nazgouee, F.3
-
37
-
-
0023886330
-
Effective immunization cutaneous leishmaniasis with defined membrane antigens reconsituted into liposomes
-
Russell, D. G., and J. Alexander. 1988. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J. Immunol. 140:1274-1279. (Pubitemid 18096704)
-
(1988)
Journal of Immunology
, vol.140
, Issue.4
, pp. 1274-1279
-
-
Russell, D.G.1
Alexander, J.2
-
38
-
-
0001902784
-
Animal models for the analysis of immune responses to leishmaniasis
-
Chapter 19, Unit 19.2
-
Sacks, D. L., and P. C. Melby. 2001. Animal models for the analysis of immune responses to leishmaniasis. Curr. Protoc. Immunol. 2001:Chapter 19, Unit 19.2.
-
(2001)
Curr. Protoc. Immunol.
, vol.2001
-
-
Sacks, D.L.1
Melby, P.C.2
-
39
-
-
0025133974
-
Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism
-
Sadick, M. D., et al. 1990. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism. J. Exp. Med. 171:115-127.
-
(1990)
J. Exp. Med.
, vol.171
, pp. 115-127
-
-
Sadick, M.D.1
-
40
-
-
7144254432
-
Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran
-
Sharifi, I., et al. 1998. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 351:1540-1543.
-
(1998)
Lancet
, vol.351
, pp. 1540-1543
-
-
Sharifi, I.1
-
41
-
-
0028929566
-
A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12
-
Skeiky, Y. A., et al. 1995. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J. Exp. Med. 181:1527-1537.
-
(1995)
J. Exp. Med.
, vol.181
, pp. 1527-1537
-
-
Skeiky, Y.A.1
-
42
-
-
0032403592
-
LeIF: A recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile
-
Skeiky, Y. A., et al. 1998. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol. 161:6171-6179.
-
(1998)
J. Immunol.
, vol.161
, pp. 6171-6179
-
-
Skeiky, Y.A.1
-
43
-
-
0024805717
-
Experimental visceral leishmaniasis: Role of endogenous IFN-gamma in host defense and tissue granulomatous response
-
Squires, K. E., et al. 1989. Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J. Immunol. 143:4244-4249. (Pubitemid 20012622)
-
(1989)
Journal of Immunology
, vol.143
, Issue.12
, pp. 4244-4249
-
-
Squires, K.E.1
Schreiber, R.D.2
McElrath, M.J.3
Rubin, B.Y.4
Anderson, S.L.5
Murray, H.W.6
-
44
-
-
0034671822
-
Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis
-
Stager, S., D. F. Smith, and P. M. Kaye. 2000. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J. Immunol. 165:7064-7071.
-
(2000)
J. Immunol.
, vol.165
, pp. 7064-7071
-
-
Stager, S.1
Smith, D.F.2
Kaye, P.M.3
-
45
-
-
77950627826
-
Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE
-
Trigo, J., et al. 2010. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine 28:3333-3340.
-
(2010)
Vaccine
, vol.28
, pp. 3333-3340
-
-
Trigo, J.1
-
46
-
-
0031842834
-
Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family
-
Webb, J. R., et al. 1998. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 66:3279-3289.
-
(1998)
Infect. Immun.
, vol.66
, pp. 3279-3289
-
-
Webb, J.R.1
-
47
-
-
0030457804
-
Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis
-
Webb, J. R., D. Kaufmann, A. Campos-Neto, and S. G. Reed. 1996. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 157:5034-5041.
-
(1996)
J. Immunol.
, vol.157
, pp. 5034-5041
-
-
Webb, J.R.1
Kaufmann, D.2
Campos-Neto, A.3
Reed, S.G.4
|